Marion R. Nadel, PhD; Jean A. Shapiro, PhD; Carrie N. Klabunde, PhD; Laura C. Seeff, MD; Robert Uhler, MA; Robert A. Smith, PhD; David F. Ransohoff, MD
Grant Support: By the National Cancer Institute (contract no. N01-PC-85169) and the Centers for Disease Control and Prevention (interagency agreement no. 99FED06571).
Potential Financial Conflicts of Interest: Consultancies: D.F. Ransohoff (EXACT Sciences Corp. until 2002).
Requests for Single Reprints: Marion Nadel, PhD, Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop K-55, Atlanta, GA 30341-3717; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Nadel, Shapiro, and Seeff and Mr. Uhler: Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop K-55, Atlanta, GA 30341-3717.
Dr. Klabunde: National Cancer Institute, EPN 4005, 6130 Executive Boulevard, Bethesda, MD 20892.
Dr. Smith: American Cancer Society, 1599 Clifton Road, Atlanta, GA 30329-4251.
Dr. Ransohoff: School of Medicine, University of North Carolina at Chapel Hill, CB#7080, Room 326 Burnett-Womack Building, Chapel Hill, NC 27599-7080.
Author Contributions: Conception and design: M.R. Nadel, J.A. Shapiro, C.N. Klabunde, L.C. Seeff, R. Uhler, D.F. Ransohoff.
Analysis and interpretation of the data: M.R. Nadel, J.A. Shapiro, C.N. Klabunde, L.C. Seeff, R. Uhler, D.F. Ransohoff.
Drafting of the article: M.R. Nadel, J.A. Shapiro, R.A. Smith.
Critical revision of the article for important intellectual content: M.R. Nadel, J.A. Shapiro, C.N. Klabunde, L.C. Seeff, R. Uhler, R.A. Smith, D.F. Ransohoff.
Final approval of the article: M.R. Nadel, J.A. Shapiro, C.N. Klabunde, L.C. Seeff, R.A. Smith, D.F. Ransohoff.
Provision of study materials or patients: C.N. Klabunde.
Statistical expertise: M.R. Nadel, R. Uhler.
Obtaining of funding: M.R. Nadel, C.N. Klabunde.
Administrative, technical, or logistic support: M.R. Nadel, C.N. Klabunde.
Collection and assembly of data: C.N. Klabunde, R. Uhler.
Nadel M., Shapiro J., Klabunde C., Seeff L., Uhler R., Smith R., Ransohoff D.; A National Survey of Primary Care Physicians' Methods for Screening for Fecal Occult Blood. Ann Intern Med. 2005;142:86-94. doi: 10.7326/0003-4819-142-2-200501180-00007
Download citation file:
Published: Ann Intern Med. 2005;142(2):86-94.
Authorities recommend at-home fecal occult blood tests (FOBTs), using 2 samples from 3 consecutive bowel movements, as one of several options for colorectal cancer screening.
The authors asked a national sample of 1147 primary care physicians about their colorectal cancer screening practices. Approximately 33% reported using only a single in-office stool sample for FOBT. To follow up positive results, approximately 30% said that they repeated the FOBT, and about the same percentage recommended sigmoidoscopy rather than total colon examination.
Many primary care physicians in the United States may use inadequate methods to screen for colorectal cancer.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Hematology/Oncology, Cancer Screening/Prevention, Gastrointestinal Cancer, Colorectal Cancer.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only